HONG KONG – China's I-Mab Biopharma Co. Ltd. entered a strategic partnering agreement with ABL Bio Inc., of South Korea. I-Mab will out-license its bispecific antibody (BsAb) for an undisclosed target to ABL Bio for about $100 million.